PD-1 / PD-L1 monoclonal antibody is named as a drug or biological intervention in 4 clinical trials in our China and USA trial registers, 3 of which are recruiting. Lead sponsors include Repertoire Immune Medicines (1), Hongmeng Yu (1) and Shanghai Zhongshan Hospital (1). Registered phases: Phase 2, Phase 1/2 and Observational. Conditions studied include Advanced Malignant Solid Tumor; Nasopharyngeal Carcinoma (NPC); Hepatocellular Carcinoma (HCC).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07444437 | A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer |
Phase 2 | Recruiting |
| NCT07781358 | Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma (NPC) |
Phase 2 | Recruiting |
| NCT07293754 | An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Malignant Solid Tumor |
Phase 1/2 | Recruiting |
| NCT07724951 | The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study (ClinicalTrials.gov ↗) Hepatocellular Carcinoma (HCC) |
Observational | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced Malignant Solid Tumor | 1 |
| Nasopharyngeal Carcinoma (NPC) | 1 |
| Hepatocellular Carcinoma (HCC) | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Repertoire Immune Medicines | 1 |
| Hongmeng Yu | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Suzhou BlueHorse Therapeutics Co., Ltd. | 1 |
| Register | PD-1 / PD-L1 monoclonal antibody trials |
|---|---|
| Clinical trials in China | 3 |
| Clinical trials in USA | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PD-1 / PD-L1 monoclonal antibody works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PD-1 / PD-L1 monoclonal antibody (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.